XML 20 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]      
Revenue [1] $ 2,554,741 $ 1,963,896 $ 1,352,013
Expenses      
Cost of revenue [1] 2,187,388 1,503,426 1,035,429
Selling, general and administrative expenses [1] 263,050 358,110 269,269
Depreciation and amortization expenses 118,370 123,415 67,195
Loss on disposal of non-strategic assets 0 8,107 0
Right-of-use assets impairment 2,588 24,065 0
Loss on lease termination 18,922 0 0
Change in fair value of contingent consideration 4,908 17,984 (23,522)
Total operating expenses 2,595,226 2,035,107 1,348,371
Operating income (loss) (40,485) (71,211) 3,642
Interest income 5,544 5,256 1,369
Interest expense (24,722) (54,205) (15,572)
Gain (loss) from equity method investees (3,441) 1,290 4,569
Loss on extinguishment/repayment on long-term debt, net 0 (21,010) (10,192)
Change in tax receivables agreement liability (173) (61,982) (45,950)
Other income (expense), net 241 (543) 57
Loss before income taxes (63,036) (202,405) (62,077)
Benefit from income taxes (1,413) (89,365) (43,376)
Loss from continuing operations (61,623) (113,040) (18,701)
Loss from discontinued operations, net of tax [2] 0 0 (463)
Loss before preferred dividends and accretion of Series A Preferred Stock (61,623) (113,040) (19,164)
Dividends and accretion of Series A Preferred Stock (31,831) (29,220) 0
Net loss attributable to common shareholders of Evolent Health, Inc. - basic (93,454) (142,260) (19,164)
Net loss attributable to common shareholders of Evolent Health, Inc. - diluted $ (93,454) $ (142,260) $ (19,164)
Basic and diluted      
Basic (in dollars per share) $ (0.81) $ (1.28) $ (0.20)
Diluted (in dollars per share) $ (0.81) $ (1.28) $ (0.20)
Weighted-average common shares outstanding      
Basic (in shares) 114,682 111,251 93,699
Diluted (in shares) 114,682 111,251 93,699
Comprehensive loss      
Net loss attributable to common shareholders of Evolent Health, Inc. $ (93,454) $ (142,260) $ (19,164)
Other comprehensive loss, net of taxes, related to:      
Foreign currency translation adjustment (496) (79) (816)
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc. $ (93,950) $ (142,339) $ (19,980)
[1] See Note 19 for amounts attributable to unconsolidated related parties included in these line items.
[2] Includes $0.5 million loss on disposal of discontinued operations for the year ended December 31, 2022.